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Abstract
Background Patients with central serous chorioretinopathy
(CSC) show an increased sympathetic activity compared to
controls. Additionally, there are several reports of increased
corticosteroid and catecholamine levels in these patients.
Obstructive sleep apnea syndrome (OSAS) has been shown to
enhance sympathetic activity depending on severity. Respira-
tory disturbance increases urinary catecholamine secretion
and is associated with the occurance of hypertension in a dose
dependent manner. Therefore we hypothesize that OSAS may
act as a risk factor for the development of CSC.
Methods Patients with active CSC or with pigment epithe-
lial disturbances after CSC were contacted to answer a
questionnaire about general health, drugs and sleeping
habits and to complete the Epworth Sleepiness Scale
(ESS) score, a widely used subjective measure of daytime
sleepiness. Patients with an ESS score of >10 were referred
to our department of pulmonary medicine for evaluating of
respiratory disturbance in sleep.
Results We identified 56 consecutive patients with angio-
graphic criteria for acute CSC or pigment epithelial defects
after CSC, seven (12.5%) of whom were excluded because
of a history of systemic or topic corticosteroid use. Thirty-
six (73.5%) of the remaining 49 patients returned the
questionnaire. Fourteen (38.8%) had an ESS score of >10.
They were referred to the Department of Pulmonary
Medicine. In eight (22.2%) of these patients, a diagnosis
of obstructive sleep apnea syndrome was confirmed.
Conclusions We found that 22% of the patients with acute
or chronic CSC in this case series also suffered from OSAS,
whereas in the general population OSAS is considerably
less frequently reported (2–4%). OSAS therefore may act as
a risk factor for the development of CSC. However,
prospective controlled data is needed to definitely evaluate
the possible association between CSC and OSAS. Also the
clinical course of CSC during treatment of OSAS would be
of particular interest.
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Introduction
Central serous chorioretinopathy (CSC) is characterized by
an idiopathic serous detachment of the neurosensory retina.
It mainly affects young adults. The etiology and pathogen-
esis of this disorder are still unknown. Maumenee described
the concept of a leakage site within the retinal pigment
epithelial layer, visible on fluorescein angiography in
patients with CSC [1]. Recent studies have indicated that
the possible site of primary pathology is the choroidal
vessels [2], and that the involvement of the retinal pigment
epithelium may play a pathogenetic role. Risk factors
Graefes Arch Clin Exp Ophthalmol (2008) 246:1225–1228
DOI 10.1007/s00417-008-0837-0
DO00837; No of Pages
The authors have full control of all primary data, and they agree to
allow Graefe’s Archive for Clinical and Experimental Ophthalmology
to review their data upon request.
Financial relationships or interests: none
P. Kloos :A. Thoelen
Department of Ophthalmology, Stadtspital Triemli,
Zürich, Switzerland
I. Laube
Department of Pulmonary Medicine, Stadtspital Triemli,
Zürich, Switzerland
P. Kloos (*)
Department of Ophthalmology, Kantonsspital St. Gallen,
9007 St. Gallen, Switzerland
e-mail: patrik.kloos@kssg.ch
including psychological stress and type-A behaviour [3],
corticosteroids [4] and sympathomimetic use [5] have been
reported to induce or exacerbate CSC. Patients with CSC
demonstrated increased heart-rate variability as a marker of
sympathetic activity compared to controls [6]. Additionally,
there are several reports of increased corticosteroid and
catecholamine levels in these patients [7]. All these
observations suggest that increased sympathetic activity
may be of importance in the pathogenesis of CSC.
Obstructive sleep apnea syndrome (OSAS) is character-
ized by repeated episodes of sleep-disruptive upper airway
closure, leading to motor restlessness, lack of refreshing
sleep and excessive daytime sleepiness [8]. OSAS has been
shown to affect catecholamine excretion levels [9] and to
enhance sympathetic activity and blood pressure, with a
clear dose effect [10].
Due to these possible common pathophysiological
factors, we hypothesize that OSAS may act as a risk factor
for the development of CSC.
Material and methods
In 2006, all 56 patients with angiographic findings of CSC
(e.g., active site of leakage and/or disturbances of the retinal
pigment epithelium on fluorescein angiography) were
contacted to answer a questionnaire about general health,
drugs and sleeping habits and the Epworth Sleepiness Scale
(ESS). When returning the completed questionnaire, the
patients also provided their informed consent to the
evaluation of their data for scientific purposes and for
further investigations. In the case of further examinations,
again they had to provide their informed consent. All
investigations and related work adhered to the tenets of the
declaration of Helsinki. The Epworth Sleepiness Scale
(ESS) is widely used as a subjective measure of daytime
sleepiness. The test measures the probability of falling
asleep in eight daily situations (scores 0–3; total possible
score of 24). ESS scores in healthy subjects differ from
those in patients with obstructive sleep apnea syndrome.
The clinically normal range is 2 to 10, and ESS scores
increase with the severity of OSAS [11]. An ESS score
of >5 identifies a respiratory disturbance index (RDI) of
>5/hour with a sensitivity of 95% and a specificity of 9%.
To diagnose OSAS, a threshold disturbance index or apnea-
hypopnea index (AHI) of 5 or more in connection with
daytime hypersomnolence was used. Cut-off points of 5, 15
and 30 events/hour were used to indicate mild, moderate
and severe levels of OSAS [12]. The ESS score in the ESS
validation study for German-speaking people without
OSAS ranged from 0 to 15, with 93% of the subjects
having a score of 10 or less [13]. Patients with an ESS
score of >10 were referred to our department of pulmonary
medicine for further investigations. Generally, the condition
of OSAS is diagnosed with an overnight polysomnography,
including cardiorespiratory parameters, oxygen saturation
Fig. 1 Chronic alteration of the
pigment epithelium and an
active site of leakage on the
fluorescein angiography (mid
and late phase) with the
corresponding detachment of the
neurosensory retina on the OCT
(6-mm horizontal scan nasal to
temporal) in a patient with CSC
and OSAS
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and electroencephalography. Patients with a history of
topical (eye and skin) inhaled or systemic corticosteroid
use, or having any endocrine disorders, were not included.
Results
Of the 56 consecutive patients with acute or chronic CSC
(diagnosed by fluorescein angiography and OCT scans),
seven (12.5%) patients were excluded because of a history
of systemic corticosteroid use. Thirty-six (73.5%) of the
remaining 49 patients returned the questionnaire, of whom
30 patients (83.3%) were men. The mean age of our
patients was 56.7 years (range 31 – 76 years). Fourteen
patients demonstrated an ESS score of >10 and were
therefore referred to the Department of Pulmonary Medi-
cine for further examinations. Eight (22.2%) of these were
diagnosed as having obstructive sleep apnea (five patients
with mild OSAS, three with moderate to severe OSAS).
Four of the eight patients with OSAS suffered from
chronic CSC with longstanding alterations of the pigment
epithelium, and the remaining four showed acute CSC with
an active site of leakage in the retinal pigment epithelium
and a detachment of the neurosensory retina. Figure 1
shows a typical case of chronic alteration of the pigment
epithelium, and Fig. 2 a questionnaire for a patient with an
ESS score >10. All the patients suffering from OSAS and
CSC were men. The body mass index (BMI) was similar in
the two groups with or without OSAS (25.8 vs 24.9, p=
0.47). Four (50%) of the eight patients with OSAS and 11
(39%) of the 28 patients without OSAS were under
treatment for arterial hypertension (Table 1).
Discussion
Previous studies have shown an association between CSC
and increased sympathetic activity [6], higher levels of
catecholamine [7] and high blood pressure [6]. Since OSAS
causes an increase in sympathetic activity and may increase
cortisol levels [9, 14], it can be speculated that patients with
OSAS are at higher risk of developing CSC than the
general population. We found that 22% of our patients with
CSC also suffered from OSAS, whereas OSAS is less
frequently reported (2–4%) in the general population [15].
OSAS may therefore play a role in the pathogenesis of
CSC. We were able to quite reliably exclude BMI as a risk
factor for CSC, as our OSAS patients had a mean BMI close
to normal, whereas a typical OSAS cohort has a BMI over
30 kg/m2. BMI in non-OSAS and OSAS patients with CSC
did not differ. With the exception of a 35-year-old patient, all
patients with CSC and OSAS were older (55–75 years) than
the population that is usually affected by CSC [16]. OSAS
frequently occurs in middle or advanced age, and both
diseases show several common pathophysiological path-
ways as mentioned. These facts are consistent with the
suggestion that OSAS might be another independent risk
factor for CSC in higher age. All factors that are known to
be associated with OSAS, such as raised sympathetic
Fig. 2 German ESS questionnaire of a CSC patient (his fluorescein
angiography and OCT scans are shown in Fig. 1) with an ESS score of
15 and diagnosed OSAS
Table 1 Patient demographics
All patients with CSC Patients with CSC without OSAS Patients with CSC and OSAS
Number of patients 36 28 (77.8%) 8 (22.2%)
Male 30 (83.3%) 22 (78.5%) 8 (100%)
Female 6 (16.7%) 6 (21.5%) 0 (0%)
Mean age (range) 56.7 years (31–76) 59.8 years (31–73) 53.6 years (35–76)
Mean ESS 8.1 7.0 12.0
Mean BMI (range) 25.3 (18.9–28.7) 24.9 (18.9–28.4) 25.8 (22.7–28.7)
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activity and increased catecholamine and corticosteroid
levels, might be risk factors for CSC in elderly people.
In a recent study, Leveque et al. [17] also postulated a
possible association between CSC and OSAS. This study
was, however, based exclusively on the Berlin Question-
naire to predict OSAS. To our knowledge, this is the first
report about patients with CSC and OSAS diagnosed by
polysomnography and pulse oximetry.
Respiratory disturbance could compromise choriocapillary
perfusion by sympathetic activation, as well as by inflamma-
tory and procoagulant mechanisms [18, 19]. Also, OSAS
may cause systemic hypertension [10], while CSC too has
been found to be associated with hypertension [20, 21].
CSC mainly affects male patients [16]. All our patients
with CSC and OSAS were men. For OSAS too, most
population-based studies have reported about two- to three-
fold higher risk for men compared to women [22].
Our report needs consideration of relevant bias. Not only
due to the questionnaires that were not returned but also
due to patients who were excluded because of the use of
corticosteroids, of 56 patients identified with CSC, only 36
were included in the final analysis. However, if all of the
non-included patients were free of OSAS, the prevalence of
OSAS would still be clearly higher than exspected.
Moreover, due to the retrospective observational design,
important physiological parameters such as surrogates of
sympathetic activity and blood pressure, but also endoge-
neous corticosteroid activity and procoagulant factors, were
not assessed for. To support the hypothesis of a common
pathophysiological pathway, the metabolic risk factors like
catecholamine and cortisol levels should be analyzed in
further studies. In addition the course of CSC under
treatment would be of particular interest.
We conclude that, in this limited retrospective case
series, an overrepresentation of OSAS in patients with CSC
was found. CSC and OSAS share common risk factors.
Therefore, OSAS might indicate patients at risk for CSC,
possibly by affecting sympathetic activity, procoagulant
factors, cortisol levels or yet undetermined factors. Pro-
spective studies are needed to confirm this concept.
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